Dustin Robinson, Esq.

Mr. Cannabis Law’s team, led by Partner Amanda Barton, Esq., served as lead counsel on all legal aspects relating to KetaMD, Inc. – a telehealth company focused on expanding access to ketamine through safe, effective, and affordable at-home treatments. The law firm assisted with the launch of KetaMD, operational compliance for KetaMD, seed round financing of KetaMD, and the acquisition of KetaMD by Braxia Scientific Corp.– a leader in the treatment and research of mental health conditions through ketamine and psychedelic medicine.

The acquisition of KetaMD by Braxia Scientific Corp created one of the most robust networks of physical ketamine clinics and virtual ketamine telehealth services. KetaMD recently launched operations in Florida, with the intention and infrastructure to expand across the nation in the coming months. Through its secure, HIPAA-compliant telemedicine platform, KetaMD hopes to revolutionize the treatment of those who are suffering from depression, anxiety, and other mental health challenges.

In June 2020, KetaMD hired Mr. Cannabis Law to help with all legal aspects related to launching one of the first ketamine telehealth companies, including corporate structuring, operational compliance, telehealth compliance, HIPPA compliance, seed round financing, and various other legal matters.

As an early mover in the industry with strong technology, KetaMD quickly attracted several publicly-traded companies interested in acquiring KetaMD. To determine the best partner, KetaMD and Mr. Cannabis Law performed significant diligence on many of these publicly-traded companies. Ultimately, KetaMD determined that Braxia was the best fit to scale the KetaMD business and to become one of the leading ketamine providers in the world. Barton of Mr. Cannabis Law was able to lead a team of attorneys to help guide KetaMD through the entire acquisition process. The transaction closed on August 2, 2022.

Dustin Robinson, Esq., founding partner of Mr. Cannabis Law, explained, “KetaMD operates at the intersection of two highly regulated industries: psychedelic medicine and telemedicine. Supporting KetaMD from launch through seed financing and all the way through acquisition demonstrates our firm’s deep expertise in highly regulated industries as well as our ability to support companies through various stages of maturation. I couldn’t be more ecstatic for our client, KetaMD, for being acquired by Braxia Scientific Corp. With Braxia’s extensive focus on clinical research led by one of the best depression researchers in the world, along with their operational experience of their brick-and-mortar clinics, the positive synergy between the companies will prove a competitive advantage as they expand their reach together in the future.”

Zappy Zapolin, co-founder of KetaMD, stated, “We spoke to various law firms and ultimately decided to work with Mr. Cannabis Law because of their deep expertise within the psychedelic space and ability to lead us through launch to acquisition. Amanda is an absolute all-star and was able to guide us at every step along the way. Beyond just being great attorneys, the Mr. Cannabis Law team shares our passion for trying to help as many people as possible with psychedelic medicines. We are grateful for their guidance and look forward to working with them as we integrate KetaMD’s operations into Braxia’s operations.”